Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2014

View Archived Issues

Sideris initiates phase I study of SP-420 in beta-thalassemia

Felicitex Therapeutics and Selvita target cancer quiescence through new collaboration

BIND Therapeutics collaborates with Merck & Co to develop nanomedicines for oncology

REP1 gene therapy granted FDA orphan drug designation for choroideremia

Idera and PPMD collaborate to develop TLR antagonist for Duchenne muscular dystrophy

QUE Oncology reports data from phase I study of Q-122

PRX-106, a plant cell-expressed recombinant fusion protein as treatment for fatty liver disease

Safety and favorable pharmacokinetic profile of GR-MD-02 supports plans for phase II trials

Karyopharm begins phase II trial of selinexor in patients with Richter's transformation

ZGN-203, a novel MetAP 2 inhibitor for weight loss and hyperphagia correction

Emergent seeks FDA approval of BioThrax for post-exposure prophylaxis indication

Sage's phase I/II study of SAGE-547 for super-refractory status epilepticus meets endpoints

Pierre Fabre patents report compounds with potential use in cancer

BeiGene researchers divulge BTK inhibitors

Crucell reports antibodies targeting RSV G protein

Astex Pharmaceuticals discloses FGFR inhibitors for cancer

AVEO Pharma designs anti-Notch 1 MAbs

TetraLogic Pharmaceuticals reports data from preclinical studies of birinapant

Researchers in Slovakia develop curcumin palladium complexes and analogues

Hanmi files Korean IND for phase I trial of RAF inhibitor

Dulaglutide now available in the U.S.

RedHill Biopharma's RHB-105 gains FDA QIDP designation

Promising interim analysis from phase IIb study of dupilumab for moderate to severe asthma

Oncothyreon and Celldex start phase I trial of MUC1 vaccine and anti-CD27 antibody combination

ELQ-337, a prodrug with enhanced delivery and efficacy in malaria models

ASK-1 inhibitor GS-444217 blocks hepatic fibrosis and steatosis in murine models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...